Trial · NCT04539379
Evaluation of Intravenous Infusion of Labetalol Versus Magnesium Sulfate
NCT04539379, Not applicable, Completed, Zagazig University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of Intravenous Infusion of Labetalol Versus Magnesium Sulfate. Trials, record NCT04539379. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04539379
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Intravenous Infusion of Labetalol Versus Magnesium Sulfate
- NCT number
- NCT04539379
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 60 participants, actual
- Lead sponsor
- Zagazig University
- Conditions
- Magnesium Sulfate, Labetalol
- Interventions
- Magnesium sulfate, Labetolol
- First posted
- 2020-09-07
- Last updated
- 2022-11-15
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | mean velocity | basal measurements before administration of the study drugs then at post-treatment one and six hours after drug administration. | mean velocity of middle cerebral artery |
| Secondary | mean end diastolic velocity | basal measurements before administration of the study drugs then at post-treatment one and six hours after drug administration. | mean end diastolic velocity of middle cerebral artery |
| Secondary | pulsatility index | basal measurements before administration of the study drugs then at post-treatment one and six hours after drug administration. | pulsatility index of middle cerebral artery |
| Secondary | cerebral perfusion pressure | basal measurements before administration of the study drugs then at post-treatment one and six hours after drug administration. | cerebral perfusion pressure |
| Secondary | occurrence of seizures | basal measurements before administration of the study drugs then at post-treatment one and six hours after drug administration. | occurrence of seizures |
| Secondary | The need for other antihypertensive drugs | post-treatment one and six hours after drug administration. | The need for other antihypertensive drugs (nifidibine, nitroglycerine, hydralazine, etc) |
| Secondary | adverse effects of the study drugs | post-treatment till 24 hours | hypotension,Bradycardia,persistent hypertension |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37074522 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04539379
GET https://conductscience.org/api/trials/v1/NCT04539379/registered